ArticleDiabetes2010
Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression.
Article in Diabetes, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 92 citations in OpenAlex.
- Sex-dimorphic tumor growth is regulated by tumor microenvironmental and systemic signals.Science advances · 2024Article
- Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models.Nature communications · 2021Article
- Disrupting Insulin and IGF Receptor Function in Cancer.International journal of molecular sciences · 2021Review
- Benzophenone-3 promotion of mammary tumorigenesis is diet-dependent.Oncotarget · 2020Article
- Hyperinsulinaemia in cancer.Nature reviews. Cancer · 2020Review
- Obesity, Type 2 Diabetes, and Cancer Risk.Frontiers in oncology · 2020Review
- Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.Nature communications · 2019Article
- Diabetes, Obesity, and Breast Cancer.Endocrinology · 2018Review
- Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.Molecular and cellular endocrinology · 2018Review
- Hyperinsulinemia Promotes Esophageal Cancer Development in a Surgically-Induced Duodeno-Esophageal Reflux Murine Model.International journal of molecular sciences · 2018Article
- 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.Oncotarget · 2017Review
- Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression.Oncogene · 2017Article
- Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors.Nature reviews. Molecular cell biology · 2016Review
- Dietary energy restriction reduces high-fat diet-enhanced metastasis of Lewis lung carcinoma in mice.Oncotarget · 2016Article
- EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.Endocrine-related cancer · 2016Article
- Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes.Diabetologia · 2016Article
- Monocyte chemotactic protein-1 deficiency reduces spontaneous metastasis of Lewis lung carcinoma in mice fed a high-fat diet.Oncotarget · 2016Article
- Pre-diagnosis blood glucose and prognosis in women with breast cancer.Cancer & metabolism · 2016Article
- Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Physiological reviews · 2015Review
- CD24(+) cells fuel rapid tumor growth and display high metastatic capacity.Breast cancer research : BCR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveType 2 diabetes increases breast cancer risk and mortality, and hyperinsulinemia has been identified as a major factor linking these two diseases. Thus, we hypothesized that pharmacological reduction of elevated insulin levels would attenuate type 2 diabetes-mediated mammary tumor progression. RESEARCH DESIGN AND
methodsWe studied mammary tumor development in MKR(+/+) mice, a nonobese, hyperinsulinemic mouse model of type 2 diabetes. MKR(+/+) mice were either crossed with mice expressing the polyoma virus middle T oncogene specifically in the mammary gland or inoculated orthotopically with the mouse mammary tumor cell lines Met-1 and MCNeuA. MKR(+/+) or control mice harboring tumors were treated with CL-316243, a specific beta3-adrenergic receptor agonist, which sensitizes insulin action but has no direct effect on the mouse mammary epithelium or Met-1 and MCNeuA cells.
resultsCL-316243 treatment significantly reduced the elevated insulin levels in MKR(+/+) mice and, as a consequence, attenuated mammary tumor progression in the three tumor models tested. This effect was accompanied by reductions in phosphorylation of insulin and IGF-I receptors in transformed mammary tissue.
conclusionsInsulin-sensitizing treatment is sufficient to abrogate type 2 diabetes-mediated mammary tumor progression. Therefore, early administration of insulin-sensitizing therapy may reduce breast cancer risk and mortality in patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.